Professional Role and Company Positioning
Teresa Brandt, PhD, serves as the Vice President of Regulatory Affairs at Avidity Biosciences, Inc., based in Carlsbad, California. She joined Avidity Biosciences in 2021 and currently holds a senior leadership role overseeing global regulatory strategies. Her role includes responsibility for regulatory affairs, clinical operations, and quality governance, demonstrated by her past title as Senior Vice President and Head of Global Regulatory and GCP Quality at the same company.
Educational Background
Dr. Brandt holds a PhD in Molecular and Cellular Biology (MCB). Specific institutions are not disclosed, but her advanced degree supports deep expertise in the biological sciences crucial to her regulatory leadership within a biopharmaceutical company focused on oligonucleotide conjugate therapeutics.
Industry Expertise and Contributions
- Teresa Brandt is recognized as a thought leader in rare disease drug development and innovative RNA-targeted therapeutics. She actively engages in scientific and regulatory discourse, as evidenced by her scheduled speaking engagements at high-profile industry events:
- #RNABench2Bedside conference (December 2024), where she highlighted Avidity’s pioneering work in advancing a new class of targeted RNA therapeutics.
- World Orphan Drug Congress (WODC) (April 2025), focusing on development strategies addressing rare diseases.
- Her contributions to Avidity’s development pipeline include involvement with clinical trials evaluating antibody–siRNA conjugates (AOCs), a novel modality Avidity is pursuing for diseases such as myotonic dystrophy.
- She is cited in literature and has authored or co-authored at least 19 scientific publications pertinent to targeted oligonucleotide therapies, with more than 1,600 citations, reflecting her influence and credibility within the scientific and regulatory communities.
Technical and Regulatory Leadership
- Dr. Brandt’s domain encompasses regulatory strategy, clinical development oversight, program and project management, and quality compliance, positioning her as a pivotal figure in aligning Avidity’s innovative product pipeline with global regulatory requirements.
- She has formerly held the title of Senior VP, Affairs & GCP Quality Head of Global Regulatory Affairs, indicating substantial responsibilities not only in regulatory submissions but also in Good Clinical Practice adherence and quality oversight at Avidity.
- Her experience likely includes engagement with FDA and other global health authorities, orchestrating regulatory filings and guiding the company through complex approval pathways for emerging therapeutic modalities.
Geographic and Organizational Context
- She operates out of San Diego/Carlsbad, California, a notable biotech hub enabling close proximity to key stakeholders and industry events.
- Avidity Biosciences is publicly listed under the ticker symbol RNA, underpinning the company's visibility in capital markets and public interest in its innovative biopharma approach.
Recent Visibility and Professional Engagement
- Teresa Brandt is publicly active on professional networks and company platforms, with repeated mentions across LinkedIn and ResearchGate evidencing her ongoing professional presence.
- She actively participates in industry conferences as a speaker and subject matter expert, representing Avidity’s strategic vision for RNA-targeted therapeutic technologies.
- Her recognized expertise and speaking engagements position her as a decision-maker and influencer regarding regulatory affairs, clinical development strategies, and quality governance at Avidity.
In summary, Teresa Brandt, PhD, embodies a critical senior leadership role at Avidity Biosciences with a strong molecular biology foundation and extensive experience in regulatory affairs related to RNA-targeted drug development. Her leadership in navigating regulatory landscapes for innovative oligonucleotide conjugates and rare disease treatments marks her as a key executive aligning product development with regulatory compliance, engaged actively with the scientific community and industry forums at a global level.
